Pre-admission
Digital Therapeutic
For Addiction.
Zero hours today.
Ninety days once prescribed.
Warmth you can feel.
Safety you can audit.
Every conversation is deterministic. The model can acknowledge, reflect, and deliver today's fixed module — and that is all. It never compares scores across days, never infers risk, never adapts the program. The warmth is real. The boundaries are engineered.
- Affect labeling Scaffolded vocabulary, not emotion-naming on demand
- Motivational reflections Acknowledge and roll with resistance. Never confront.
- Fixed content delivery Identical module for every user in Week 3
- Hard-coded safety Crisis keywords route deterministically to national lines
Click any message to see what the system does \u2014 and what it doesn\u2019t
The waitlist is the highest-risk period in
the entire treatment journey.
A patient is diagnosed, referred, and sent home with a waitlist number. They wait — often arriving at therapy in worse shape than the day they left, if they arrive at all.
Motivation built during intake erodes week by week. Crisis care, emergency presentations, and treatment dropouts compound — paid by GKV, absorbed by clinics.
Two daily check-ins, weekly clinical modules, on-demand skills, recovery audio. The patient arrives at therapy stable, engaged, and prepared. The clinic does nothing extra.
On the path to Class I.
Not there yet. Building openly.
Kontexa START is in active development. The clinical content, safety architecture, and validation protocol are designed. CE marking, the BfArM DiGA listing, and a PZN are the next milestones — not assumptions on this page.
Clinical content build, safety architecture, partner alignment, controlled validation in design with leading German academic and clinical partners.
Prospective controlled study against the current standard of care for the waitlist — which is nothing.
Self-certified Class I medical device. No adaptive clinical logic means no Notified Body.
BfArM DiGA-Verzeichnis listing, PZN issuance, prescribable on Muster 16, reimbursed via §33a SGB V.
Built for the people
who close the gap.
Every waitlist member who slips backwards turns into a cost elsewhere in the system — crisis care, readmission, a longer and more expensive treatment. A single GKV-reimbursed DiGA prescription intervenes at the cheapest possible point.
You diagnose. You refer. Then the wait erodes every gain. Once listed, Kontexa will be one PZN at intake — no IT integration, no staff training, no ongoing management. We are recruiting partner clinics for the validation cohort now.
Validation in collaboration with leading German academic and clinical partners. Designed as a Class I medical device under MDR. Three-layer deterministic safety architecture.
A study designed against
a control condition of nothing.
Prospective controlled validation, designed with leading German academic and clinical partners. Primary endpoint: PHQ-ADS at weeks 0, 6, 13. Secondary: percent days abstinent via Timeline Followback.